Circulating estrogen metabolites and risk of breast cancer in postmenopausal women

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 7, 2014, Pages 1290-1297

  Arslan, Alan A ^a,b   Koenig, Karen L ^a   Lenner, Per ^c   Afanasyeva, Yelena ^a   Shore, Roy E ^d   Chen, Yu ^a,b   Lundin, Eva ^c   Toniolo, Paolo ^a,b   Hallmans, Göran ^c   Zeleniuch Jacquotte, Anne ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UMEÅ UNIVERSITY   (Sweden)

^d RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; ESTROGEN RECEPTOR; ESTRONE; 2-HYDROXYESTRONE; ESTROGEN; ESTRONE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYDROXYLATION; MAJOR CLINICAL STUDY; METABOLISM; METABOLITE; POSTMENOPAUSE; PRIORITY JOURNAL; BLOOD; BREAST TUMOR; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; RISK;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGENS; ESTRONE; FEMALE; HUMANS; HYDROXYESTRONES; MIDDLE AGED; POSTMENOPAUSE; RISK;

EID: 84903985341     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0009     Document Type: Article

References (46)

1. Key TJ, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988;24: 29-3.
2. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993;15: 48-65.
3. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995; 87: 190-7.
4. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94: 606-6.
5. Muti P. The role of endogenous hormones in the etiology and prevention of breast cancer: the epidemiological evidence. Recent Results Cancer Res 2005;166: 245-6.
6. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344: 276-5.
7. Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. Breast Cancer Res 2003;5: 239-7.
8. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354: 270-82.
9. Schneider J, Huh MM, Bradlow HL, Fishman J. Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 1984;259: 4840-5.
10. Vandewalle B, Lefebvre J. Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol Cell Endocrinol 1989;61: 239-6.
11. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-hydroxyestrone: the 'good' estrogen. J Endocrinol 1996;150 Suppl: S259-S265.
12. Telang NT, Katdare M, Bradlow HL, Osborne MP. Estradiol metabolism: an endocrine biomarker for modulation of human mammary carcinogenesis. Environ Health Perspect 1997;105 Suppl 3: 559-64.
13. Gupta M, McDougal A, Safe S. Estrogenic and antiestrogenic activities of 16alpha-And 2-hydroxy metabolites of 17beta-estradiol in MCF-7 and T47D human breast cancer cells. J Steroid Biochem Mol Biol 1998;67: 413-9.
14. Kono S, Merriam GR, Brandon DD, Loriaux DL, Lipsett MB, Fujino T. Radioimmunoassay and metabolic clearance rate of catecholestrogens, 2-hydroxyestrone and 2-hydroxyestradiol in man. J Steroid Biochem 1983;19: 627-3.
15. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J. Estradiol 16 alpha-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci U S A 1985;82: 6295-9.
16. Suto A, Bradlow HL, Wong GY, Osborne MP, Telang NT. Experimental down-regulation of intermediate biomarkers of carcinogenesis in mouse mammary epithelial cells. Breast Cancer Res Treat 1993;27: 193-02.
17. Bradlow HL, Davis DL, Lin G, Sepkovic D, Tiwari R. Effects of pesticides on the ratio of 16 alpha/2-hydroxyestrone: a biologic marker of breast cancer risk. Environ Health Perspect 1995;103 Suppl 7: 147-0.
18. Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci U S A 1982;79: 3047-1.
19. Fishman J, Schneider J, Hershcope RJ, Bradlow HL. Increased estrogen-6 alpha-hydroxylase activity in women with breast and endometrial cancer. J Steroid Biochem 1984;20: 1077-81.
20. Osborne MP, Bradlow HL, Wong GY, Telang NT. Upregulation of estradiol C16 alpha-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J Natl Cancer Inst 1993;85: 1917-0.
21. Kabat GC, Chang CJ, Sparano JA, Sepkovie DW, Hu XP, Khalil A, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997;6: 505-9.
22. Ho GH, Luo XW, Ji CY, Foo SC, Ng EH. Urinary 2/16 alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singapore 1998;27: 294-9.
23. Zheng W, Dunning L, Jin F, Holtzman J. Correspondence re: G. C. Kabat et al. Urinary estrogen metabolites and breast cancer: a casecontrol study. Cancer Epidemiol., Biomark. Prev., 6: 505-09, 1997.
24. Cancer Epidemiol Biomarkers Prev 1998;7: 85-6.
25. Kabat GC, O'Leary ES, Gammon MD, Sepkovic DW, Teitelbaum SL, Britton JA, et al. Estrogen metabolism and breast cancer. Epidemiology 2006;17: 80-8.
26. Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998;78: 1250-5.
27. Muti P, Bradlow HL, Micheli A, Krogh V, FreudenheimJL, Schunemann HJ, et al. Estrogen metabolismand risk of breast cancer: a prospective study of the 2: 16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000;11: 635-0.
28. Arslan AA, Shore RE, Afanasyeva Y, Koenig KL, Toniolo P, Zeleniuch-Jacquotte A. Circulating estrogen metabolites and risk for breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev 2009;18: 2273-9.
29. Eliassen AH, Spiegelman D, Xu X, Keefer LK, Veenstra TD, Barbieri RL, et al. Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Cancer Res 2012; 72: 696-706.
30. Cauley JA,Zmuda JM, Danielson ME, Ljung BM, Bauer DC,Cummings SR, et al. Estrogen metabolites and the risk of breast cancer in older women. Epidemiology 2003;14: 740-4.
31. Wellejus A, Olsen A, Tjonneland A, Thomsen BL, Overvad K, Loft S. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev 2005;14: 2137-2.
32. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxy-And 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17: 2029-5.
33. Obi N, Vrieling A, Heinz J, Chang-Claude J. Estrogen metabolite ratio: Is the 2-hydroxyestrone to 16alpha-hydroxyestrone ratio predictive for breast cancer? Int J Womens Health 2011;3: 37-1.
34. Mackey RH, Fanelli TJ, Modugno F, Cauley JA, McTigue KM, Brooks MM, et al. Hormone therapy, estrogen metabolism, and risk of breast cancer in the Women's Health Initiative Hormone Therapy Trial. Cancer Epidemiol Biomarkers Prev 2012;21: 2022-2.
35. Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, et al. Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2012;104: 326-9.
36. Falk RT, Brinton LA, Dorgan JF, Fuhrman BJ, Veenstra TD, Xu X, et al. Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study. Breast Cancer Res 2013;15: R34.
37. Dallal CM, Tice JA, Buist DS, Bauer DC, Lacey JV, Cauley JA, et al. Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B-FIT. Carcinogenesis 2014;35: 346-5.
38. Hallmans G, Agren A, Johansson G, Johansson A, Stegmayr B, Jansson JH, et al. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort -evaluation of risk factors and their interactions. Scand J Public Health Suppl 2003;61: 18-4.
39. Klug TL, Bradlow HL, Sepkovic DW. Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2-And 16 alpha-hydroxyestrone in urine. Steroids 1994;59: 648-5.
40. Ziegler RG, Rossi SC, Fears TR, Bradlow HL, Adlercreutz H, Sepkovic D, et al. Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine. Environ Health Perspect 1997; 105 Suppl 3: 607-4.
41. Bradlow HL, Sepkovic DW, Klug T, Osborne MP. Application of an improved ELISA assay to the analysis of urinary estrogen metabolites. Steroids 1998;63: 406-3.
42. Falk RT, Rossi SC, Fears TR, Sepkovic DW, Migella A, Adlercreutz H, et al. A new ELISA kit for measuring urinary 2-hydroxyestrone, 16alpha- hydroxyestrone, and their ratio: reproducibility, validity, and assay performance after freeze-Thaw cycling and preservation by boric acid. Cancer Epidemiol Biomarkers Prev 2000;9: 81-7.
43. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-Term results of a prospective study. Br J Cancer 2004;90: 153-9.
44. Faupel-Badger JM, Fuhrman BJ, Xu X, Falk RT, Keefer LK, Veenstra TD, et al. Comparison of liquid chromatography-Tandem mass spectrometry, RIA, and ELISA methods for measurement of urinary estrogens. Cancer Epidemiol Biomarkers Prev 2010;19: 292-00.
45. Nigrovic V. [In vivo inactivation of alkaline phosphatase with DTPA and EDTA]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1964; 249: 206-4.
46. Zeleniuch-Jacquotte A, Shore RE, Afanasyeva Y, Lukanova A, Sieri S, Koenig KL, et al. Postmenopausal circulating levels of 2-And 16alphahydroxyestrone and risk of endometrial cancer. Br J Cancer 2011; 105: 1458-64.